Luís Eduardo Cruvinel Pinto
Research Subjects
Luís Eduardo Cruvinel Pinto has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Peduti Halah
Division of Pediatric Endocrinology—Department of Pediatrics, Ribeirão Preto Medical School University of São Paulo Brazil
2 shared publications - Sonir Roberto Antonini
University of São Paulo
2 shared publications - Thais Milioni Luciano
Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, (SP), Brasil
2 shared publications - Adriane Cardoso-Demartini
Setor de Endocrinologia Pediátrica Professor Romolo Sandrini, Departamento de Pediatria do Complexo Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brasil
1 shared publication - Aline Scheidemantel
Setor de Endocrinologia Pediátrica Professor Romolo Sandrini, Departamento de Pediatria do Complexo Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brasil
1 shared publication - Davi Casale Aragon
Universidade de São Paulo, Brasil
1 shared publication
Latest Publications
- 30 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , e2300-e2311
From Premature Adrenarche to Adult Metabolic Risk and Hyperandrogenism: A Systematic Review and Meta-Analysis
Context: Idiopathic premature adrenarche (IPA) has been associated with a higher risk of metabolic and reproductive dysfunction, but long-term/adult outcomes remain incompletely known. Objective: To assess the relationship between IPA and metabolic syndrome, as well as polycystic ovarian syndrome, in premenarcheal adolescent and adult women. Methods: We conducted a systematic review and meta-analysis of observational studies reporting outcomes in females with IPA after menarche. Databases were searched through February 2025. Primary outcomes included BMI, insulin resistance markers, and clinical and biochemical markers of hyperandrogenism. Data were pooled using random-effects models. The GRADE approach was applied to assess the certainty of evidence. Results: A total of 21 studies comprising 635 females with IPA and 307 age-matched controls were included. Compared to controls, IPA individuals showed significantly higher BMI (MD: 1.4; CI: 1.0 to 1.9), fasting insulin, and HOMA-IR, indicating persistent insulin resistance. Markers of hyperandrogenism, including Ferriman-Gallwey score, DHEAS, and FAI, were also elevated. Secondary analyses revealed higher triglycerides, lower HDL, increased leptin, and greater carotid intima-media thickness, supporting an early pattern of cardiometabolic risk. GRADE assessment rated most outcomes as low certainty. Conclusion: Women with a history of IPA are at increased risk of long-term insulin resistance and hyperandrogenism, with early signs of adverse cardiometabolic profiles. These findings support the need for long-term monitoring in this population.
- 30 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , e2300-e2311
From Premature Adrenarche to Adult Metabolic Risk and Hyperandrogenism: A Systematic Review and Meta-Analysis
Context: Idiopathic premature adrenarche (IPA) has been associated with a higher risk of metabolic and reproductive dysfunction, but long-term/adult outcomes remain incompletely known. Objective: To assess the relationship between IPA and metabolic syndrome, as well as polycystic ovarian syndrome, in premenarcheal adolescent and adult women. Methods: We conducted a systematic review and meta-analysis of observational studies reporting outcomes in females with IPA after menarche. Databases were searched through February 2025. Primary outcomes included BMI, insulin resistance markers, and clinical and biochemical markers of hyperandrogenism. Data were pooled using random-effects models. The GRADE approach was applied to assess the certainty of evidence. Results: A total of 21 studies comprising 635 females with IPA and 307 age-matched controls were included. Compared to controls, IPA individuals showed significantly higher BMI (MD: 1.4; CI: 1.0 to 1.9), fasting insulin, and HOMA-IR, indicating persistent insulin resistance. Markers of hyperandrogenism, including Ferriman-Gallwey score, DHEAS, and FAI, were also elevated. Secondary analyses revealed higher triglycerides, lower HDL, increased leptin, and greater carotid intima-media thickness, supporting an early pattern of cardiometabolic risk. GRADE assessment rated most outcomes as low certainty. Conclusion: Women with a history of IPA are at increased risk of long-term insulin resistance and hyperandrogenism, with early signs of adverse cardiometabolic profiles. These findings support the need for long-term monitoring in this population.
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-11
Quality of life outcomes in Brazilian adults with childhood-onset growth hormone deficiency: impact of transition-age growth hormone therapy
Objective: This study evaluated the QoL of Brazilian adult patients with childhood-onset growth hormone deficiency GHD (CO-GHD), comparing those who continued GH replacement therapy (GHRT) after transition to adulthood with those who discontinued treatment and with healthy subjects. Subjects and methods: In this cross-sectional study, quality of life (QoL) was assessed using the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in 61 Brazilian adults aged 18-50 years. The sample included 31 patients with CO-GHD confirmed during the transition period, who continued or discontinued GHRT, and 30 matched controls. Results: GHD patients had poorer QoL, as indicated by higher QoLAGHDA scores than controls (median 8 [IQR 5-14] vs 4 [IQR 2-8]; p < 0.01). Continued GHRT in adulthood did not impact QoL compared with discontinued GHRT (8 [IQR 6-16] vs. 9 [IQR 5-12], p = 0.33). Overall, women had lower QoL irrespective of GHD (9 [IQR 6-13] vs. 5 [IQR 2-8.5], p = 0.01, women and men, respectively). We found no association between QoL-AGHDA scores and education level (p = 0.51), short stature (p = 0.78), associated pituitary deficiencies (p = 0.34), or overweight/obesity (p = 0.16). Conclusion: GHD impairs quality of life in young adults; however, our cross-sectional cohort did not show significant improvements in quality of life associated with GH replacement therapy. A multidisciplinary approach combining individualized treatment and psychosocial interventions remains essential.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (5) , 1-11
Open AccessQuality of life outcomes in Brazilian adults with childhood-onset growth hormone deficiency: impact of transition-age growth hormone therapy
Objective: This study evaluated the QoL of Brazilian adult patients with childhood-onset growth hormone deficiency GHD (CO-GHD), comparing those who continued GH replacement therapy (GHRT) after transition to adulthood with those who discontinued treatment and with healthy subjects. Subjects and methods: In this cross-sectional study, quality of life (QoL) was assessed using the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in 61 Brazilian adults aged 18-50 years. The sample included 31 patients with CO-GHD confirmed during the transition period, who continued or discontinued GHRT, and 30 matched controls. Results: GHD patients had poorer QoL, as indicated by higher QoLAGHDA scores than controls (median 8 [IQR 5-14] vs 4 [IQR 2-8]; p < 0.01). Continued GHRT in adulthood did not impact QoL compared with discontinued GHRT (8 [IQR 6-16] vs. 9 [IQR 5-12], p = 0.33). Overall, women had lower QoL irrespective of GHD (9 [IQR 6-13] vs. 5 [IQR 2-8.5], p = 0.01, women and men, respectively). We found no association between QoL-AGHDA scores and education level (p = 0.51), short stature (p = 0.78), associated pituitary deficiencies (p = 0.34), or overweight/obesity (p = 0.16). Conclusion: GHD impairs quality of life in young adults; however, our cross-sectional cohort did not show significant improvements in quality of life associated with GH replacement therapy. A multidisciplinary approach combining individualized treatment and psychosocial interventions remains essential.
- Open Access
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (1) , 1-9
Adult height of children born small for gestational age treated with growth hormone and gonadotropin-releasing hormone analogs in Southern Brazil
Objective: To evaluate adult height and identify the factors contributing to its achievement in patients born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH). Subjects and methods: This retrospective study includes data of SGA children treated at a pediatric endocrinology center. Inclusion criteria were SGA birth (birth length and/or weight < -1.28 standard deviation score (SDS), absence of catch-up growth by the age of four years, rhGH treatment for more than 12 months, and recorded [...] ABSTRACT Objective: To evaluate adult height and identify the factors contributing to its achievement in patients born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH). Subjects and methods: This retrospective study includes data of SGA children treated at a pediatric endocrinology center. Inclusion criteria were SGA birth (birth length and/or weight < -1.28 standard deviation score (SDS), absence of catch-up growth by the age of four years, rhGH treatment for more than 12 months, and recorded
- 1 January 2025
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (1) , 1-9
Open AccessAdult height of children born small for gestational age treated with growth hormone and gonadotropin-releasing hormone analogs in Southern Brazil
Objective: To evaluate adult height and identify the factors contributing to its achievement in patients born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH). Subjects and methods: This retrospective study includes data of SGA children treated at a pediatric endocrinology center. Inclusion criteria were SGA birth (birth length and/or weight < -1.28 standard deviation score (SDS), absence of catch-up growth by the age of four years, rhGH treatment for more than 12 months, and recorded [...] ABSTRACT Objective: To evaluate adult height and identify the factors contributing to its achievement in patients born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH). Subjects and methods: This retrospective study includes data of SGA children treated at a pediatric endocrinology center. Inclusion criteria were SGA birth (birth length and/or weight < -1.28 standard deviation score (SDS), absence of catch-up growth by the age of four years, rhGH treatment for more than 12 months, and recorded
- Open Access
- 1 July 2002
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 110 (1) , 39-41
The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist
- 1 July 2002
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 110 (1) , 39-41
Open AccessThe risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist